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Abstract 
 
BACKGROUND AND OBJECTIVE: 
Surgical mortality in the US is widely perceived to be superior to that in the UK. 
However, previous comparisons of surgical outcome in the two countries have often 
failed to take sufficient account of case-mix or examine long-term outcome. The 
standardised nature of liver transplantation practice makes it uniquely placed for 
undertaking reliable international comparisons of surgical outcome. The objective of 
this study is to undertake a risk-adjusted disease-specific comparison of both short- 
and long-term survival of liver transplant recipients in the UK and Ireland with that in 
the US. 
 
DESIGN, SETTING AND PARTICIPANTS: 
Multi-centre cohort study using two high quality national databases including all 
adults who underwent a first single organ liver transplant in the UK and Ireland 
(n=5,925) and the US (n=41,866) between March 1994 and March 2005. 
 
MAIN OUTCOME MEASURES:  
Post-transplant mortality during the first 90 days, 90 days-1 year and beyond the first 
year, adjusted for recipient and donor characteristics. 
 
RESULTS: 
Risk-adjusted mortality in the UK and Ireland was generally higher than in the US 
during the first 90 days (hazard ratio 1.17 95%CI 1.07-1.29), both for patients 
transplanted for acute liver failure (hazard ratio 1.27 95%CI 1.01-1.60) as well as 
those transplanted for chronic liver disease (hazard ratio 1.18 95% CI 1.07-1.31). 
Between 90 days and 1 year post-transplantation, no statistically significant 
differences in overall risk-adjusted mortality were noted between the two cohorts. 
Survivors of the first post-transplant year in the UK and Ireland had lower overall risk-
adjusted mortality than those transplanted in the US (hazard ratio 0.88 95%CI 0.81- 
0.96). This difference was observed among patients transplanted for chronic liver 
disease (hazard ratio 0.88 95%CI 0.81-0.96) but not those transplanted for acute 
liver failure (hazard ratio 1.02 95%CI 0.70-1.50). 
 
CONCLUSIONS:  
Whilst risk-adjusted mortality is higher in the UK and Ireland during the first 90 days 
following liver transplantation, it is higher in the US among those liver transplant 
recipients who survived the first post-transplant year. Our results are consistent with 
the notion that the US has superior acute peri-operative care whereas the UK 
appears to provide better quality chronic care following liver transplantation surgery. 
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Introduction 
 
International comparisons of health care outcomes and practices provide a unique 
opportunity for benchmarking and allow policymakers and clinicians to identify areas 
of health care delivery where countries could learn from each other.1 Surgical 
mortality in the US is widely perceived to be superior to that in the UK. Previous 
transatlantic comparisons of surgical outcome have reported that, compared to the 
US, the UK has a four-fold higher risk-adjusted inpatient mortality rate following major 
non-cardiac surgery,2 higher unadjusted one-year mortality among heart transplant 
recipients (23% vs. 14%)3 and similar unadjusted one-year mortality among elective 
adult first liver transplant recipients in the year 2000 (13.5% vs. 12%) in the face of 
some evidence of less severe liver disease.4 Those comparisons have however 
failed to take sufficient account of case-mix or examine long-term outcome.  
Given the standardised nature of liver transplantation practice, which makes it 
uniquely placed for undertaking reliable international comparisons of surgical 
outcome and the fact that risk-adjusted post-transplant survival is a function of the 
underlying liver disease,5 we carried out a disease-specific risk-adjusted comparison 
of both short- and long-term patient survival following liver transplantation in the UK 
and Ireland and the US between 1st March 1994 and 31st March 2005. 
 
 
Materials and Methods 
 
Databases 
We used the databases of the UK and Ireland Liver Transplant Audit and the Organ 
Procurement and Transplantation Network/ United Network for Organ Sharing 
(OPTN/UNOS). Detailed descriptions of these databases and evidence of their 
completeness, accuracy and reliability have been published elsewhere.6-8 The study 
population included all adults (aged 16 years or older) who received a first liver 
transplant in the three countries between 1st March 1994 and 31st March 2005. 
Patients who underwent multi-organ transplantation, those who had received a 
previous liver transplant and those with missing survival data (3 in the UK and Ireland 
and 2 in the US) were excluded. 
 
Data management 
The two databases were harmonised to ensure that liver disease classification and 
risk factor definitions were comparable. 
We adopted a 10 category chronic liver disease classification system (table 1) similar 
to that used by Roberts et al.5  
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Table 1: Liver disease classification scheme 
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Diseases 
 
1 Primary biliary cirrhosis (PBC) 
 
Primary biliary cirrhosis 
2 Primary sclerosing cholangitis (PSC) 
 
Primary sclerosing cholangitis (with Crohn’s disease; ulcerative 
colitis; no bowel disease; other) 
 
3 Alcoholic liver disease (ALD) 
 
Alcoholic cirrhosis; acute alcoholic hepatitis  
4 Auto-immune and cryptogenic disease (AID) 
 
Cirrhosis (autoimmune; cryptogenic; drug/ industrial exposure; 
chronic active hepatitis- aetiology unknown; type non A, non B; 
uncertain or unknown aetiology); giant cell hepatitis 
  
5 Hepatitis C cirrhosis (HCV) 
 
Cirrhosis (type C; type B and C); alcoholic cirrhosis with hepatitis C 
 
6 Hepatitis B cirrhosis (HBV) 
 
Cirrhosis (type B- HBsAg+; type B and D; type D) 
7 Acute liver failure (ALF) Fulminant hepatic failure; acute hepatic necrosis (type A; type B- 
HBsAg+; type non A- non B; type C; type D, type B and C; type B 
and D; drug induced- paracetamol; drug [not paracetamol]/ toxin- 
induced; aetiology unknown; trauma; ischaemic; postoperative; 
other) 
 
8 Cancer 
 
Primary liver malignancy (hepatocellular carcinoma [HCC]- non-
cirrhotic; HCC and cirrhosis; fibrolamellar; cholangiocarcinoma; 
hepatoblastoma; haemangioendothelioma-haemangiosarcoma; 
other); bile duct cancer; secondary hepatic malignancy 
 
9 Metabolic liver disease 
 
Alpha-1-antitrypsin deficiency; Wilson's disease(acute; chronic); 
haemochromatosis – haemosiderosis; cirrhosis (non-alcoholic 
steatohepatitis [NASH]; fatty liver disease); TPN/ hyperalimentation-
induced liver disease; glycogen storage disease type I; glycogen 
storage disease type II; hyperlipidaemia type II- homozygous 
hypercholestrolaemia; tyrosinaemia; primary oxalosis/oxaluria- 
hyperoxaluria; maple syrup urine disease; amyloidosis; sarcoidosis; 
haemophilia; von Willebrand’s disease; Crigler-Najjar syndrome; 
urea cycle disorder; other metabolic disease 
 
10 Other liver diseases 
 
Cirrhosis (type A; non-specified viral hepatitis; other); secondary 
biliary cirrhosis (Caroli's disease; choledochal cyst; other); familial 
cholestasis (Byler's disease; other); cholestatic liver disease-other; 
neonatal cholestatic liver disease; biliary atresia or hypoplasia 
(extrahepatic; biliary hypoplasia-nonsyndromic paucity; biliary 
hypoplasia- Alagille’s syndrome; other); idiopathic adulthood 
ductopaenia; cystic fibrosis; congenital hepatic fibrosis; Budd-Chiari 
syndrome (acute; chronic); portal vein thrombosis; benign tumour 
(hepatic adenoma; polycystic liver disease; other); graft versus host 
disease; trauma; nodular regenerative hyperplasia; other, not 
already noted above; not reported 
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Patients were classified according to both diagnostic code and, if present, free text 
diagnosis. In line with previous studies,9-11 we assigned patients to the acute liver 
failure category only if their diagnostic details were consistent with this designation 
and were also transplanted at the highest listing urgency status (i.e. “super-urgent” 
status in the UK and Ireland and UNOS status 1 in the US). In order to ensure that, in 
the event of multiple diagnoses, patients were assigned to the diagnosis which is 
deemed most likely to influence their prognosis, disease classification was 
undertaken in a hierarchical order: cancer, hepatitis C cirrhosis and primary 
sclerosing cholangitis. For example, patients with a coded diagnosis of hepatitis C 
cirrhosis and a free text diagnosis of hepatocellular carcinoma were assigned to the 
“Cancer” category and so were patients with incidental malignant tumours found in 
the explanted liver. All patients with Wilson’s disease and Budd-Chiari syndrome 
were assigned to the metabolic and other liver diseases categories, respectively 
regardless of the mode of their disease presentation. 
For the purposes of multivariable analyses, creatinine was set to 4.0mg/dL for those 
with lower values who received renal support immediately prior to transplantation. 
Implausible values of body mass index (<10 kg/m2 or >100 kg/m2), cold ischaemic 
time (>40 hours), serum bilirubin (< 0.1 mg/dL), serum creatinine (<0.1 mg/dL or >15 
mg/dL) and serum albumin (<0.7 g/dL or >6.0 g/dL) were considered to be missing. 
The Model for End-stage Liver Disease (MELD) score, an objective widely used 
method of predicting liver disease mortality without transplantation, was calculated 
using serum creatinine, serum total bilirubin and International Normalised Ratio (INR) 
of prothrombin time values obtained immediately before transplantation as described 
by UNOS12 with the exceptions that no upper or lower limits were applied to the score 
and hepatocellular carcinoma recipients and other special cases were not awarded 
extra points. A high MELD score corresponds to a poorer prognosis. 
 
Statistical Analyses 
We used survival analysis to analyse mortality after liver transplantation. Patients lost 
to follow up were censored at the date of last follow up. Patients requiring a second 
graft were not censored at the time of re-transplantation. Unadjusted mortality 
estimates were calculated using the Kaplan-Meier method. Piecewise proportional 
hazard regression13 was used to generate overall and disease-specific hazard ratios 
(HR) indicating the relative risk of death in the UK and Ireland versus the US in the 
following time periods after liver transplantation: the first 90 days, 90 days to 1 year 
and beyond the first year. Thus, HRs greater than 1 indicate that the mortality in the 
UK and Ireland is higher than in the US. The analysis was censored at 10 years post-
transplantation. Only those clinically plausible recipient and donor risk factors that 
were well-recorded to a comparable degree in both databases with non-missing 
values of over 80% were included in the regression models. Those risk factors were: 
liver disease category, recipient age, race, body mass index (BMI), serum albumin, 
serum bilirubin, serum creatinine, requirement for pre-operative renal support, 
requirement for pre-operative ventilation and history of previous upper abdominal 
surgery, graft type, organ cold ischaemic time, donor age, type, cause of death and 
BMI, donor/ recipient gender match, donor/ recipient blood group match, donor/ 
recipient cytomegalovirus serology match and year of transplantation. We 
categorised BMI according to the World Health Organization guidelines as follows: 
non-obese (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), obese (≥30.0 kg/m2) or 
underweight (<18.5 kg/m2). All other numerical data were used as continuous 
variables in the multivariable analyses. 
Information on every variable included in the risk models was available for 30,493 
patients (63.8%). Variables with the highest percentage of missingness included 
donor/ recipient cytomegalovirus serology match (15.0%), organ cold ischaemic time 
(12.2%), donor body mass index (7.7%) and recipient history of previous upper 
abdominal surgery (5.6%). All other variables used had rates of missingness 
between 0% and 4%. 
To ensure that patients with missing values were not excluded from the analysis, we 
used the technique of multiple imputation as described by Royston.14,15 Missing 
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values were imputed 10 times using switching regression to create 10 complete 
datasets which were each independently analysed. Analyses were then pooled to 
give final estimates. 
We also carried out two sets of additional analyses. The first was restricted to 
patients with acute liver failure and included aetiology (paracetamol vs. non-
paracetamol-induced) in the risk model in addition to the above described risk 
factors. The second entailed repeating all the analyses having included transplant 
centre volume in the risk models. In line with previous studies,16,17 transplant centre 
volume (defined as the average number of adult single organ liver transplants, 
including re-transplants, performed during the study period at a given centre per 
year) was used as dichotomous variable with a cut-off of 20 transplants per year. For 
the purposes of all analyses incorporating transplant centre volume, the standard 
errors of the estimates were adjusted in order to account for the possibility of 
transplant centre clustering.18 
 
All analyses were performed using Stata version 9 (StataCorp, College Station, TX). 
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Results 
 
Clinical Characteristics 
Between the 1st March 1994 and 31st March 2005, 5,925 adults received a first single 
organ liver transplant at 8 centres in the UK and Ireland while 41,866 such 
transplants were performed at 137 centres in the US. The mean annual transplant 
centre volume in the UK and Ireland was significantly larger than in the US (table 2).  
 
Table 2: Distribution of clinical characteristics at time of transplantation in the 
UK and Ireland and the US between 1st March 1994 and 31st March 2005 
Characteristic UK and 
Ireland US 
UK and 
Ireland US 
UK and 
Ireland US 
Number of recipients 5,925 41,866 773 1,507 5,152 40,359 
Recipient age (years) 48.6 (12.5)       50.4 (10.8)      36.5 (13.2)      38.5 (14.1)      50.4 (11.4)      50.8 (10.4)      
Recipient gender (% male) 56.1 63.2 33.0 33.1 59.6 64.3 
Recipient race (%) 
   white 
   non-white 
 
86.3 
13.7 
 
87.0 
13.0 
 
87.3 
12.7 
 
71.3 
28.7 
 
86.1 
13.9 
 
87.6 
12.4 
Recipient BMI (kg/m2)  25.4 (4.9)  27.7 (5.8) 24.3 (5.0) 26.8 (6.3) 25.5 (4.9)  27.7 (5.8) 
Albumin (g/dL)  3.0 (0.7)     2.9 (0.7) 2.8 (0.9) 2.8 (0.6) 3.0 (0.6) 2.9 (0.7) 
Bilirubin (mg/dL)  7.5 (9.6) 6.8 (9.6) 17.0 (12.5) 20.1 (12.5) 6.1 (8.2) 6.3 (9.1) 
Creatinine (mg/dL)  1.5 (1.2) 1.3 (1.1) 2.8 (1.6) 2.2 (1.9) 1.3 (0.9) 1.3 (1.0) 
Calculated MELD score 20.2 (11.0) 19.5 (9.6)  39.8 (9.6) 35.0 (9.0) 17.3 (7.9) 19.0 (9.1) 
Pre-operative renal support (%) 12.8 4.2 50.3 17.1 7.2 3.7 
Pre-operative ventilation (%) 11.0 5.9 73.7 52.4 1.6 4.1 
Previous upper abdominal surgery (%) 18.3 35.8 8.1 18.8 19.9 36.3 
Graft type (%) 
   whole 
   segmental 
 
94.4 
5.6 
 
94.4 
5.6 
 
91.6 
8.4 
 
96.6 
3.4 
 
94.9 
5.1 
 
94.4 
5.6 
Cold ischaemic time (minutes) 658.1 (190.1) 497.3 (240.7) 601.0 (190.1) 486.6 (242.2) 666.8 (188.6) 497.7 (240.6) 
Donor age (years) 42.7 (15.0) 38.4 (17.4) 41.7 (15.6) 36.9 (17.7) 42.8 (14.9)  38.5 (17.4) 
Donor type (%) 
   cadaveric heart-beating 
   living 
   cadaveric non-heart-beating 
 
98.6 
0.4 
1.0 
 
94.6 
4.1 
1.3 
 
99.9 
0 
0.1 
 
97.8 
1.1 
1.1 
 
98.5 
0.4 
1.1 
 
94.4 
4.2 
1.4 
Donor cause of death (%) 
   trauma 
   cerebrovascular accident 
   cerebral anoxia 
   other 
 
21.1 
64.5 
6.7 
7.7 
 
45.1 
42.9 
9.1 
2.9 
 
20.8 
65.7 
6.8 
6.7 
 
44.6 
42.7 
9.5 
3.2 
 
21.1 
64.4 
6.7 
7.8 
 
45.1 
42.9 
9.1 
2.9 
Donor BMI (kg/m2) 24.8 (4.3) 25.4 (5.8) 24.3 (4.0) 25.1 (5.9) 24.9 (4.3) 25.5 (5.8) 
Donor/ Recipient gender match (%) 
   male/ male 
   female/ male 
   male/ female 
   female/ female 
 
35.3 
20.8 
18.2 
25.7 
 
40.6 
22.5 
19.1 
17.8 
 
18.4 
14.6 
31.8 
35.2 
 
20.3 
12.7 
37.7 
29.3 
 
37.8 
21.8 
16.2 
24.2 
 
41.3 
22.9 
18.4 
17.4 
Donor/ Recipient blood group match (%) 
   identical 
   compatible 
   incompatible 
 
89.8 
9.7 
0.5 
 
91.7 
7.4 
0.9 
 
67.0 
32.3 
0.7 
 
66.6 
27.9 
5.5 
 
93.2 
6.3 
0.5 
 
92.6 
6.7 
0.7 
Donor/ Recipient CMV match (%) 
   positive match 
   positive mismatch 
   negative match 
 
64.2 
17.7 
18.1 
 
68.2 
18.9 
12.9 
 
52.2 
24.8 
23.0 
 
71.1 
16.4 
12.5 
 
65.7 
16.8 
17.5 
 
68.0 
19.0 
13.0 
Re-transplantation requirement (%) 9.0 8.0 10.7 9.3 8.7 8.0 
Annual transplant centre volume  95.5 (38.7) 67.7 (46.9)  96.9 (41.0) 68.7 (50.3)  95.3 (38.3)   67.7 (46.8) 
Values are means (standard deviation) unless indicated as percentages 
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The age, gender and racial distributions of the two cohorts were similar. The 
commonest indications for liver transplantation were primary biliary cirrhosis and 
alcoholic liver disease in the UK and Ireland and HCV cirrhosis in the US (table 3).  
 
 
Table 3: Frequency (%) of liver disease categories in liver transplant 
recipients in the UK and Ireland and the US between 1st March 1994 and 
31st March 2005
 
 
 
Disease category 
 
 
UK and Ireland 
n=5,925 
 
US 
n=41,866 
  Overall 
  Acute liver failure (ALF) 
  Chronic liver disease (CLD) 
    Primary biliary cirrhosis (PBC) 
    Primary sclerosing cholangitis (PSC) 
    Alcoholic liver disease (ALD) 
    Auto-immune and cryptogenic disease (AID)  
    Hepatitis C cirrhosis (HCV) 
    Hepatitis B cirrhosis (HBV) 
    Cancer 
    Metabolic liver disease 
    Other liver diseases 
100.0 
13.1 
86.9 
15.2 
8.5 
15.2 
10.8 
13.1 
4.0 
11.7 
4.7 
3.7 
100.0 
3.6 
96.4 
5.7 
6.7 
13.7 
13.7 
37.7 
4.3 
6.9 
4.8 
2.9 
 
 
 
Compared to their US counterparts, liver transplant recipients in the UK and Ireland 
were far more likely to be transplanted for acute liver failure or cancer, had a greater 
requirement for pre-operative renal support, were less often mechanically ventilated 
immediately prior to transplantation, had a significantly longer donor organ cold 
ischaemic time, were more likely to receive grafts from older donors who had 
succumbed as a result of a cerebrovascular accident (as opposed to trauma) and 
had slightly lower mean MELD scores, except among patients transplanted for acute 
liver failure whose MELD scores were higher in the UK and Ireland. It is important to 
note however that MELD scores could not be calculated in 54.3% of US patients 
because their INR data were not available. 
 
Post-transplant mortality  
The 5-year mortality of patients transplanted for chronic liver disease in the UK and 
Ireland was similar to that observed in the US (27.1% 95%CI 25.8-28.5 vs. 28.3% 
95%CI 27.8-28.8), whereas the 5-year mortality of those transplanted for acute liver 
failure was higher in the UK and Ireland (34.1% 95%CI 30.7-37.8 vs. 29.1% 95%CI 
26.7-31.6). A disease-specific comparison of the 5-year mortality within patients 
transplanted for chronic liver disease produced similar findings with the exception of 
higher mortality among patients transplanted for primary sclerosing cholangitis in the 
UK and Ireland (figure 1). 
In contrast, the 90-day mortality was higher in the UK and Ireland than in the US both 
among patients transplanted for acute liver failure (24.9% 95%CI 22.0-28.1 vs. 
18.2% 95%CI 16.3-20.2) and chronic liver disease (9.4% 95%CI 8.6-10.2 vs. 8.0% 
95%CI 7.7-8.2). A disease-specific comparison within patients transplanted for 
chronic liver disease revealed a similar pattern except in patients with alcoholic liver 
disease who had slightly lower 90-day mortality in the UK and Ireland (figure 1). 
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In both cohorts, the 5-year mortality was lowest among primary biliary cirrhosis 
recipients and highest among patients transplanted for cancer followed by those 
transplanted for acute liver failure and hepatitis C cirrhosis. 
 
Risk-adjusted comparisons 
Risk-adjusted mortality (figure 2) in the first 90 days was significantly higher in the UK 
and Ireland than in the US (HR 1.17 95%CI 1.07-1.29, p<0.001), both for patients 
transplanted for acute liver failure (HR 1.27 95%CI 1.01-1.60, p<0.04) and those 
transplanted for chronic liver disease (HR 1.18 95%CI 1.07-1.31, p<0.001). Mortality 
between 90 days and 1 year was similar between the two overall cohorts. Compared 
to their US counterparts, patients who survived the first post-transplant year in the 
UK and Ireland had a lower overall risk-adjusted mortality (HR 0.88 95%CI 0.81-0.96, 
p<0.004). This difference was observed among patients transplanted for chronic liver 
disease (HR 0.88 95%CI 0.81-0.96, p<0.003) but not those transplanted for acute 
liver failure (HR 1.02 95%CI 0.70-1.50, p=0.9). 
Disease-specific risk-adjusted comparisons largely reflected the overall results for 
chronic liver disease, although there were some notable exceptions. For example, 
the mortality between 90 days and 1 year was significantly higher in the UK and 
Ireland among patients transplanted for primary sclerosing cholangitis (HR 1.70 
95%CI 1.04-2.78, p<0.03). 
 
Additional analyses 
When paracetamol hepatotoxicity (n=278 in the UK and Ireland vs. n=160 in the US)  
was included in the risk model, the mortality of patients transplanted for acute liver 
failure in the UK and Ireland remained significantly higher during the first 90 days 
than that of their US counterparts (HR 1.33 95%CI 1.06-1.68, p<0.02).  
Similarly, the differences in overall risk-adjusted mortality between the two cohorts 
persisted even after differences in transplant centre volume were accounted for in the 
risk model (≤90 days: HR 1.22 95%CI 1.01-1.47 p<0.04, 90days-1 year: HR 0.97 
95%CI 0.84-1.12 p=0.7, >1 year: HR 0.89 95%CI 0.80-0.99 p<0.03).      
 
 
Discussion 
 
We found that the mortality in the first 90 days after adult first single organ liver 
transplantation was higher in the UK and Ireland than in the US, but lower in patients 
who survived the first year. This trend was apparent across most liver disease 
categories both with and without risk-adjustment. 
 
Methodological limitations
 
Well-recognised differences in the aetiology of acute liver failure exist between the 
two cohorts. Paracetamol hepatotoxicity is a far commoner cause of acute liver 
failure necessitating liver transplantation in the UK and Ireland than the US (36.0% 
vs. 10.6% in our study) and is also associated with poorer transplant outcomes than 
other causes of acute liver failure.9 This could account for the greater pre-operative 
requirements for renal and ventilatory support we observed among patients 
transplanted for acute liver failure in the UK and Ireland, However, it is unlikely that 
these case-mix differences have contributed to the higher early mortality of this group 
in the UK and Ireland given that the differences in mortality in the first 90 days 
between the two cohorts remained when we adjusted for paracetamol hepatotoxicity 
in the risk model. 
A further limitation relates to potential differences in data quality between the two 
databases. However, both databases are mandatory national liver transplant 
registries and have robust quality assurance procedures ensuring high standards of 
timely and complete data submission, validation and ascertainment of post-transplant 
adverse events6-8,19 thereby making suboptimal data quality an unlikely explanation 
for the observed mortality differences. In particular, the inferior long-term mortality 
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among US liver transplant recipients cannot be accounted for by differences in the 
percentage of patients who were lost to follow up (3.9% in the UK and Ireland vs. 
8.1% in the US). 
 
Explanations for the observed differences 
Although our comparison was risk-adjusted, it is still conceivable that the observed 
mortality differences could be explained by residual confounding. For example, a 
number of clinically plausible risk factors were not included in the regression model 
that we used for risk-adjustment, because they had high frequencies of missing data 
in either database (e.g. MELD), were not recorded in a format that allows direct and 
reliable comparison (e.g. encephalopathy) or were likely to be differently defined (e.g. 
requirement for hospitalization). However, we believe that residual confounding is an 
unlikely explanation because our risk model included the vast majority of previously 
identified recipient and donor risk factors of post-liver transplant outcome.20,21 With 
regards to MELD, we6 and others22,23 have previously shown it to be a poor predictor 
of post-transplant mortality and, hence, its omission from the multivariable analyses 
is highly unlikely to have made a significant difference to our results. Similarly, 
although our analysis did not take account of waiting time for the procedure (which is 
considerably longer in the US4), it is inconceivable that this has influenced our results 
since previous studies have clearly demonstrated that longer waiting time does not 
predict more severe liver disease at transplantation6 or higher mortality either pre- or 
post-operatively.24-28 
Whilst transplant centre volume has an important,16,29 albeit waning,17 influence on 
post-liver transplant outcomes, we felt it inappropriate to adjust for it in an 
international comparison of two healthcare systems because it potentially reflects the 
efficiency of organisation and delivery of a given country’s healthcare system.19 
However, the results of our additional analyses, which incorporated this parameter in 
the risk models, suggest that it cannot explain the observed differences in post-
transplant mortality between the two cohorts. 
It is noteworthy that the cold ischaemic time, a measure of the efficiency of the organ 
procurement and distribution process and an important determinant of graft survival, 
is significantly longer in the UK and Ireland than in the US. The likely reasons for this 
require further study but might relate to logistic delays in organ retrieval and 
implantation. However, given the fact that it was included in the risk-adjustment, cold 
ischaemic time cannot account for the higher early mortality observed in the UK and 
Ireland. 
The remaining explanation for the observed mortality differences is a genuine 
difference in quality of care. The observation that short-term mortality following liver 
transplantation is higher in the UK and Ireland than the US is consistent with 
previously reported differences in risk-adjusted hospital mortality following major non-
cardiac surgery.2 Significant corresponding differences have been documented 
between the two healthcare systems in nurse-patient ratios2,30,31 and provision of 
intensive care32-35 both of which have been shown to be inversely associated with 
excess surgical hospital mortality.2,30,31,36-42 The observed early mortality differences 
could also reflect differences in donor appraisal and selection practices between the 
two cohorts. A survey of UK and US liver transplant surgeons in 200243 showed that 
American surgeons adopt a more conservative approach with regards to utilizing 
steatotic donor livers, known to be associated with inferior short-term outcomes,44-48 
placing far greater emphasis on histological assessment than their British 
counterparts. Other factors that might affect the quality of care in this period could 
include differences in operator expertise and/or commitment to other surgical 
disciplines and differences in immunosuppressive and antibiotic protocols. 
The higher risk-adjusted mortality among US survivors of the first post-transplant 
year, compared to those transplanted in the UK and Ireland, is likely to have other 
explanations. One possibility could be that US liver transplant programmes are good 
at prolonging, beyond the first post-transplant year, the survival of those high risk 
recipients who would have otherwise died early had they been transplanted in the UK 
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and Ireland. However, given the fact that risk-adjustment was equally applied to all 
time periods; we believe this possibility is unlikely. 
The factors that predict long-term post-liver transplant mortality have been poorly 
investigated but may include immunosuppressive strategies, management of 
complications of immunosuppression and disease recurrence as well as 
management of co-morbidities. Some of these factors might be different in the two 
cohorts. For example, McGlynn et al49 found that only 56% of Americans received 
recommended medical care for a range of chronic conditions, including diabetes, 
hypertension and hyperlipidaemia, all of which are known to be highly prevalent 
among liver transplant recipients.50 Other possible explanations could relate to 
differences in strength of primary care infrastructure51,52 as well as equity of access 
to, and costs of healthcare in the two cohorts. The 2002 Commonwealth Fund 
International Health Policy Survey found that sicker adults in the US are far more 
likely than those in the UK to forgo medical care and fail to comply with 
recommended follow up and treatment, because of costs.53 More recently, a 
comparison of prevalence rates of self-reported illnesses and biological markers of 
disease in the two countries54 concluded that US residents are much less healthy 
than their English counterparts, especially those at the bottom of the socioeconomic 
hierarchy. Moreover, health insurance status was shown to be an independent 
predictor of 5-year mortality among US liver transplant recipients55 whereas the 
extension of Medicare insurance coverage of immunosuppressive medications 
beyond 1 year after kidney transplantation in the US resulted in a significant 
improvement of both patient and graft survival.56,57  
Interestingly, similar findings to those found in our study were recently reported in a 
risk-adjusted comparison of mortality among survivors of the first year after kidney 
transplantation between the US and Canada,58 another country with a universal 
healthcare system such as that in the UK and Ireland. 
The observed survival difference among those transplanted for primary sclerosing 
cholangitis, which unlike other diseases is apparent up to a year after 
transplantation, is intriguing. Whether this reflects differences in surgical technique59 
or is simply due to a type 1 error, could not be ascertained from our data and merits a 
further study. 
 
Future 
Whilst long-term survival in most disease categories was similar between patients 
transplanted in UK and Ireland and the US, the time course of the mortality is 
different. The factors responsible for those differences and whether they continue 
beyond 10 years require more detailed analyses. Further research is also necessary 
to confirm our hypothesis that the observed differences in mortality after liver 
transplantation reflect more generic differences in peri-operative and long-term care 
between the two healthcare systems. 
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Figure captions and footnotes 
(CAPTION) 
Figure 1: Kaplan-Meier survival graphs by liver disease category for liver 
transplant recipients in the UK and Ireland (dashed line) and the US 
solid line) between 1st March 1994 and 31st March 2005 
(FOOTNOTE)
 
Abbreviations: ALF= acute liver failure, CLD= chronic liver disease, PBC= primary biliary 
cirrhosis, PSC= primary sclerosing cholangitis, ALD= alcoholic liver disease, AID= auto-immune 
and cryptogenic disease, HCV= hepatitis C cirrhosis, HBV= hepatitis B cirrhosis, Metabolic= 
metabolic liver disease, other= other liver diseases 
(CAPTION) 
Figure 2: Unadjusted and adjusted hazard ratios (and 95% confidence 
intervals) for mortality in the first 90 days, 90 days-1 year and beyond 
the first post-transplant year* in the UK and Ireland (n=5,925) compared 
to the US (n=41,866) by liver disease category 
(FOOTNOTE) 
*The analysis was censored at 10 years post-transplantation. 
Abbreviations: ALF= acute liver failure, CLD= chronic liver disease, PBC= primary biliary 
cirrhosis, PSC= primary sclerosing cholangitis, ALD= alcoholic liver disease, AID= auto-immune 
and cryptogenic disease, HCV= hepatitis C cirrhosis, HBV= hepatitis B cirrhosis, Metabolic= 
metabolic liver disease, other= other liver diseases 
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